tiprankstipranks
Trending News
More News >

Virax Biolabs Announces CFO Resignation and Transition

Story Highlights
Virax Biolabs Announces CFO Resignation and Transition

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).

On June 13, 2025, Virax Biolabs Group Limited announced the resignation of Jason Davis from his roles as Chief Financial Officer and Secretary. His departure is not due to any disagreements with the company’s operations or policies. Despite his resignation, Mr. Davis will continue to support the company as an independent consultant, focusing on audit coordination and financial administration.

The most recent analyst rating on (VRAX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.

More about Virax Biolabs Group Ltd. Class A

Virax Biolabs Group Limited is a company based in the United Kingdom, operating within the biolabs industry. The company focuses on providing innovative solutions and services in the biotechnology sector.

Average Trading Volume: 143,189

Technical Sentiment Signal: Sell

Learn more about VRAX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1